Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date

References

• MozaffarianDBenjaminEJGoASHeart disease and stroke statistics – 2016 update: a report from the American Heart AssociationCirculation20161334e38e36026673558
   PubMed Web of Science ®Google Scholar
• FordESAjaniUACroftJBExplaining the decrease in U.S. deaths from coronary disease, 1980–2000N Engl J Med2007356232388239817554120
   PubMed Web of Science ®Google Scholar
• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
   PubMed Web of Science ®Google Scholar
• ErratumLancet2013381986762823439101
   PubMedGoogle Scholar
• MoranAEForouzanfarMHRothGAThe global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 studyCirculation2014129141493150124573351
   PubMed Web of Science ®Google Scholar
• NicholsMTownsendNScarboroughPRaynerMTrends in age-specific coronary heart disease mortality in the European Union over three decades: 1980–2009Eur Heart J201334393017302723801825
   PubMed Web of Science ®Google Scholar
• AmbrosyAPFonarowGCButlerJThe global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registriesJ Am Coll Cardiol201463121123113324491689
   PubMed Web of Science ®Google Scholar
• HeidenreichPAAlbertNMAllenLAForecasting the impact of heart failure in the United States: a policy statement from the American Heart AssociationCirc Heart Fail20136360661923616602
   PubMed Web of Science ®Google Scholar
• BahramiHKronmalRBluemkeDADifferences in the incidence of congestive heart failure by ethnicity: the Multi-ethnic Study of AtherosclerosisArch Intern Med2008168192138214518955644
   PubMed Web of Science ®Google Scholar
• BraunwaldEThe war against heart failure: the Lancet lectureLancet2015385997081282425467564
   PubMed Web of Science ®Google Scholar
• GoASMozaffarianDRogerVLHeart disease and stroke statistics – 2014 update: a report from the American Heart AssociationCirculation20141293e28e29224352519
   PubMed Web of Science ®Google Scholar
• VigenRMaddoxTMAllenLAAging of the United States population: impact on heart failureCurr Heart Fail Rep20129436937422940871
   PubMedGoogle Scholar
• DunlaySMRedfieldMMWestonSAHospitalizations after heart failure diagnosis: a community perspectiveJ Am Coll Cardiol200954181695170219850209
   PubMed Web of Science ®Google Scholar
• Ministério da SaúdeInformation about morbidity: hospital admission2014 Available from: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sih/cnv/niuf.defAccessed December 24, 2015
   Google Scholar
• No authors listedEffects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)N Engl J Med198731623142914352883575
   PubMed Web of Science ®Google Scholar
• No authors listedEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failureN Engl J Med199132552933022057034
   PubMed Web of Science ®Google Scholar
• PittBZannadFRemmeWJThe effect of spironolactone on morbidity and mortality in patients with severe heart failureN Engl J Med19993411070971710471456
   PubMed Web of Science ®Google Scholar
• McMurrayJJCONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin angiotensin aldosterone system the cornerstone of therapy for systolic heart failureEur J Heart Fail201113992993621816763
   PubMed Web of Science ®Google Scholar
• No authors listedEffect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)Lancet199935391692001200710376614
   PubMed Web of Science ®Google Scholar
• No authors listedThe Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trialLancet1999353914691310023943
   PubMed Web of Science ®Google Scholar
• PackerMCoatsAJFowlerMBEffect of carvedilol on survival in severe chronic heart failureN Engl J Med2001344221651165811386263
   PubMed Web of Science ®Google Scholar
• ShibataMCFlatherMDWangDSystematic review of the impact of beta blockers on mortality and hospital admissions in heart failureEur J Heart Fail20013335135711378007
   PubMed Web of Science ®Google Scholar
• LevyDKenchaiahSLarsonMGLong-term trends in the incidence of and survival with heart failureN Engl J Med2002347181397140212409541
   PubMed Web of Science ®Google Scholar
• RogerVLWestonSARedfieldMMTrends in heart failure incidence and survival in a community-based populationJAMA2004292334435015265849
   PubMed Web of Science ®Google Scholar
• BarkerWHMulloolyJPGetchellWChanging incidence and survival for heart failure in a well-defined older population, 1970–1974 and 1990–1994Circulation2006113679980516461823
   PubMed Web of Science ®Google Scholar
• FonarowGCAbrahamWTAlbertNMFactors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HFArch Intern Med2008168884785418443260
   PubMedGoogle Scholar
• GuhaKMcDonaghTHeart failure epidemiology: European perspectiveCurr Cardiol Rev20139212312723597298
   PubMedGoogle Scholar
• RogerVLEpidemiology of heart failureCirc Res2013113664665923989710
   PubMed Web of Science ®Google Scholar
• YusufSRangarajanSTeoKCardiovascular risk and events in 17 low-, middle-, and high-income countriesN Engl J Med2014371981882725162888
   PubMed Web of Science ®Google Scholar
• McMurrayJJPackerMDesaiASAngiotensin-neprilysin inhibition versus enalapril in heart failureN Engl J Med201437111993100425176015
   PubMed Web of Science ®Google Scholar
• LevinERGardnerDGSamsonWKNatriuretic peptidesN Engl J Med199833953213289682046
   PubMed Web of Science ®Google Scholar
• BaxterGFThe natriuretic peptidesBasic Res Cardiol2004992717514963664
   PubMed Web of Science ®Google Scholar
• PandeyKNBiology of natriuretic peptides and their receptorsPeptides200526690193215911062
   PubMed Web of Science ®Google Scholar
• VolpeMNatriuretic peptides and cardio-renal diseaseInt J Cardiol2014176363063925213572
   PubMed Web of Science ®Google Scholar
• PotterLRAbbey-HoschSDickeyDMNatriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functionsEndocr Rev2006271477216291870
   PubMed Web of Science ®Google Scholar
• RubattuSSciarrettaSValentiVStanzioneRVolpeMNatriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseasesAm J Hypertens200821773374118464748
   PubMed Web of Science ®Google Scholar
• VolpeMCarnovaliMMastromarinoVThe natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatmentClin Sci (Lond)20161302577726637405
   PubMed Web of Science ®Google Scholar
• SonnenbergJLSakaneYJengAYIdentification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidneyPeptides1988911731802966343
   PubMed Web of Science ®Google Scholar
• SeguraJRuilopeLMDual-acting angiotensin receptor-neprilysin inhibitionCurr Hypertens Rep2011131747821046489
   PubMed Web of Science ®Google Scholar
• BevanEGConnellJMDoyleJCandoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertensionJ Hypertens19921076076131321186
   PubMed Web of Science ®Google Scholar
• RichardsAMWittertGACrozierIGChronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin IIJ Hypertens19931144074168390508
   PubMed Web of Science ®Google Scholar
• McDowellGCoutieWShawCBuchananKDStruthersADNichollsDPThe effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptidesBr J Clin Pharmacol19974333293329088591
   PubMed Web of Science ®Google Scholar
• FerroCJSprattJCHaynesWGWebbDJInhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivoCirculation19989723232323309639376
   PubMed Web of Science ®Google Scholar
• AndoSRahmanMAButlerGCSennBLFlorasJSComparison of candoxatril and atrial natriuretic factor in healthy men: effects on hemodynamics, sympathetic activity, heart rate variability, and endothelinHypertension1995266 Pt 2116011667498988
   PubMed Web of Science ®Google Scholar
• ClelandJGSwedbergKLack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failureLancet19983519116165716589620738
   PubMed Web of Science ®Google Scholar
• BurnettJCJrVasopeptidase inhibition: a new concept in blood pressure managementJ Hypertens199917Suppl 1S37S43
   Google Scholar
• RoblJASunCQStevensonJDual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidaseJ Med Chem19974011157015779171867
   PubMed Web of Science ®Google Scholar
• TrippodoNCRoblJAAsaadMMFoxMPanchalBCSchaefferTREffects of omapatrilat in low, normal, and high renin experimental hypertensionAm J Hypertens1998113 Pt 13633729544878
   PubMed Web of Science ®Google Scholar
• LiaoWCVesterqvistODelaneyCPharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjectsBr J Clin Pharmacol200356439540612968984
   PubMed Web of Science ®Google Scholar
• MitchellGFIzzoJLJrLacourcièreYOmapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the Conduit Hemodynamics of Omapatrilat International Research StudyCirculation2002105252955296112081987
   PubMed Web of Science ®Google Scholar
• RouleauJLPfefferMAStewartDJComparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trialLancet2000356923061562010968433
   PubMed Web of Science ®Google Scholar
• PackerMCaliffRMKonstamMAComparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)Circulation2002106892092612186794
   PubMed Web of Science ®Google Scholar
• KostisJBPackerMBlackHRSchmiederRHenryDLevyEOmapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trialAm J Hypertens200417210311114751650
   PubMed Web of Science ®Google Scholar
• FryerRMSegretiJBanforPNEffect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedemaBr J Pharmacol2008153594795518084312
   PubMed Web of Science ®Google Scholar
• BlumbergALDennySEMarshallGRNeedlemanPBlood vessel-hormone interactions: angiotensin, bradykinin, and prostaglandinsAm J Physiol19772323H305H310842686
   PubMedGoogle Scholar
• CampbellDJVasopeptidase inhibition: a double-edged sword?Hypertension200341338338912623931
   PubMed Web of Science ®Google Scholar
• BraunwaldEThe path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failureJ Am Coll Cardiol201565101029104125766951
   PubMed Web of Science ®Google Scholar
• GuJNoeAChandraPAl-FayoumiSLigueros-SaylanMPharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor(ARNi)J Clin Pharmacol201050440141419934029
   PubMed Web of Science ®Google Scholar
• HegdeLGYuCRennerTConcomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the ratJ Cardiovasc Pharmacol201157449550421297495
   PubMed Web of Science ®Google Scholar
• CicardiMZingaleLCBergamaschiniLAgostoniAAngioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatmentArch Intern Med2004164891091315111379
   PubMedGoogle Scholar
• MistryNBWestheimASKjeldsenSEThe angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trialsExpert Opin Pharmacother20067557558116553573
   PubMed Web of Science ®Google Scholar
• KsanderGMGhaiRDde JesusRDicarboxylic acid dipeptide neutral endopeptidase inhibitorsJ Med Chem19953810168917007752193
   PubMed Web of Science ®Google Scholar
• RademakerMTCharlesCJEspinerEANichollsMGRichardsAMKosoglouTCombined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin IIJ Cardiovasc Pharmacol19983111161259456286
   PubMed Web of Science ®Google Scholar
• McMurrayJJAdamopoulosSAnkerSDESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEur Heart J201233141787184722611136
   PubMed Web of Science ®Google Scholar
• YancyCWJessupMBozkurtB2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20136216e147e23923747642
   PubMed Web of Science ®Google Scholar
• JessupMNeprilysin inhibition – a novel therapy for heart failureN Engl J Med2014371111062106425176014
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• BlankfieldRPTo the editor: the PARADIGM-HF trialCleve Clin J Med201683316726974982
   PubMed Web of Science ®Google Scholar
• No authors listedEffect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractionsN Engl J Med1992327106856911463530
   PubMed Web of Science ®Google Scholar
• CohnJNJohnsonGZiescheSA comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failureN Engl J Med199132553033102057035
   PubMed Web of Science ®Google Scholar
• No authors listedClinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison: the NETWORK investigatorsEur Heart J19981934814899568453
   PubMed Web of Science ®Google Scholar
• NanasJNAlexopoulosGAnastasiou-NanaMIOutcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter studyJ Am Coll Cardiol20003672090209511127445
   PubMed Web of Science ®Google Scholar
• KomajdaMLutigerBMadeiraHTolerability of carvedilol and ACE-inhibition in mild heart failure: results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)Eur J Heart Fail20046446747515182773
   PubMed Web of Science ®Google Scholar
• Messner PellencPRudnickiALeclercqFGrolleauREnalapril in the treatment of mild-to-moderate heart failure in general medical practice: a prospective and multicentre study concerning 17,546 patientsActa Cardiol19955031872017676758
   PubMed Web of Science ®Google Scholar
• McMurrayJJPackerMDesaiASDual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM-HF)Eur J Heart Fail20131591062107323563576
   PubMed Web of Science ®Google Scholar
• SabeMAJacobMSTaylorDOIn reply: the PARADIGM-HF trialCleve Clin J Med201683316716826974983
   PubMed Web of Science ®Google Scholar
• CorreiaLCRassiAJrParadigm-HF: a paradigm shift in heart failure treatment?Arq Bras Cardiol20161061777926815651
   PubMed Web of Science ®Google Scholar
• SabeMAJacobMSTaylorDOA new class of drugs for systolic heart failure: the PARADIGM-HF studyCleve Clin J Med2015821069370126469827
   PubMed Web of Science ®Google Scholar
• PackerMMcMurrayJJVDesaiASAngiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failureCirculation20151311546125403646
   PubMed Web of Science ®Google Scholar
• JhundPSFuMBayramEEfficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HFEur Heart J201536382576258426231885
   PubMed Web of Science ®Google Scholar
• KaplinskyEPARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?J Geriatr Cardiol201512547047326512236
   PubMedGoogle Scholar
• BrownNJRayWASnowdenMGriffinMRBlack Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedemaClin Pharmacol Ther19966018138689816
   PubMed Web of Science ®Google Scholar
• SolomonSDClaggettBDesaiASInfluence of ejection fraction on outcomes and efficacy of sacubitril/valsartan (LCZ696) in heart failure with reduced ejection fraction: the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trialCirc Heart Fail201693e00274426915374
   PubMed Web of Science ®Google Scholar
• BhardwajAJanuzziJLJrNatriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithmCrit Pathw Cardiol20098414615019952548
   PubMedGoogle Scholar
• MotiwalaSRJanuzziJLJrThe role of natriuretic peptides as biomarkers for guiding the management of chronic heart failureClin Pharmacol Ther2013931576723187878
   PubMed Web of Science ®Google Scholar
• VolpeMRubattuMBurnettJJrNatriuretic peptides in cardiovascular diseases: current use and perspectivesEur Heart J201435741942524227810
   PubMed Web of Science ®Google Scholar
• CharlesCJEspinerEANichollsMGClearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheepAm J Physiol19962712 Pt 2R373R3808770137
   PubMedGoogle Scholar
• SolomonSDZileMPieskeBThe angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialLancet201238098511387139522932717
   PubMed Web of Science ®Google Scholar
• KristensenSLPreissDJhundPSRisk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trialCirc Heart Fail201691e00256026754626
   PubMed Web of Science ®Google Scholar
• MinersJSBaruaNKehoePGGillSLoveSAβ-degrading enzymes: potential for treatment of Alzheimer diseaseJ Neuropathol Exp Neurol2011701194495922002425
   PubMed Web of Science ®Google Scholar
• NalivaevaNNBelyaevNDKerridgeCTurnerAJAmyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer’s diseaseFront Aging Neurosci2014623525278875
   PubMed Web of Science ®Google Scholar
• Novartis PharmaceuticalsEfficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients with Preserved Ejection Fraction (PARAGON-HF) Available from: https://clinicaltrials.gov/ct2/show/NCT01920711. NLM identifier: NCT01920711Accessed January 4, 2016
   Google Scholar
• DawsonLAMaitlandNJTurnerAJUsmaniBAStromal-epithelial interactions influence prostate cancer cell invasion by altering the balance of metallopeptidase expressionBr J Cancer20049081577158215083188
   PubMed Web of Science ®Google Scholar
• SmollichMGötteMYipGWOn the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancerBreast Cancer Res Treat2007106336136917295044
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and ResearchApplication number: 207620orig1s000 – summary review2015 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000SumR.pdfAccessed January 4, 2016
   Google Scholar
• RuilopeLMDukatABöhmMLacourcièreYGongJLefkowitzMPBlood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyLancet201037597221255126620236700
   PubMed Web of Science ®Google Scholar
• KarioKSunNChiangFTEfficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled studyHypertension201463469870524446062
   PubMed Web of Science ®Google Scholar
• KarioKTamakiYOkinoNGotouHZhuMZhangJLCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor: the first clinical experience in patients with severe hypertensionJ Clin Hypertens (Greenwich)201618430831426402918
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGBainRPThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathyN Engl J Med199332920145614628413456
   PubMed Web of Science ®Google Scholar
• RuggenentiPPernaAGherardiGRenoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuriaLancet1999354917635936410437863
   PubMed Web of Science ®Google Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• LipkinGWDawnayABHarwoodSMCattellWRRaineAEEnhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failureKidney Int19975237928019291201
   PubMed Web of Science ®Google Scholar
• JudgePHaynesRLandrayMJBaigentCNeprilysin inhibition in chronic kidney diseaseNephrol Dial Transplant201530573874325140014
   PubMed Web of Science ®Google Scholar
• Mattace-RasoFUvan der CammenTJHofmanAArterial stiffness and risk of coronary heart disease and stroke: the Rotterdam StudyCirculation2006113565766316461838
   PubMed Web of Science ®Google Scholar
• WeberTAuerJO’RourkeMFArterial stiffness, wave reflections, and the risk of coronary artery diseaseCirculation2004109218418914662706
   PubMed Web of Science ®Google Scholar
• FordMLTomlinsonLAChapmanTPRajkumarCHoltSGAortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4Hypertension20105551110111520212269
   PubMed Web of Science ®Google Scholar
• RomanMJDevereuxRBKizerJRCentral pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart StudyHypertension200750119720317485598
   PubMed Web of Science ®Google Scholar
• BooysenHLNortonGRMasekoMJAortic, but not brachial blood pressure category enhances the ability to identify target organ changes in normotensivesJ Hypertens20133161124113023552129
   PubMed Web of Science ®Google Scholar
• RomanMJOkinPMKizerJRLeeETHowardBVDevereuxRBRelations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart StudyJ Hypertens201028238438820051906
   PubMed Web of Science ®Google Scholar
• WilliamsBCockcroftJRKarioKRationale and study design of the Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor with Angiotensin Receptor Blocker Measuring Arterial Stiffness in the Elderly (PARAMETER) studyBMJ Open201442e004254
   PubMed Web of Science ®Google Scholar
• YoungJBDunlapMEPfefferMAMortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsCirculation2004110172618262615492298
   PubMed Web of Science ®Google Scholar
• PittBSegalRMartinezFARandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE)Lancet199734990547477529074572
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• KlaiberMKruseMVölkerKNovel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2Basic Res Cardiol2010105558359520352235
   PubMed Web of Science ®Google Scholar
• KimDAizawaTWeiHAngiotensin II increases phosphodi-esterase 5A expression in vascular smooth muscle cells: a mechanism by which angiotensin II antagonizes cGMP signalingJ Mol Cell Cardiol200538117518415623434
   PubMed Web of Science ®Google Scholar
• FrantzSKlaiberMBabaHAStress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase IEur Heart J201334161233124422199120
   PubMed Web of Science ®Google Scholar